Sign in
CompletedNo phase

Alpha-s1 Casein Hydrolysate on Sleep

Key facts

Who runs it
Kuang Tien General Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
38 people enrolled
Started
1 May 2019
Ended
30 Nov 2023
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • alpha-s1 casein hydrolysate
  • Maltodextrin
Record updated
10 January 2024

Who can take part

Age
20 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • age between 20 and 80 who meet the diagnostic criteria for chronic insomnia according to the International Classification of Sleep Disorders (ICSD) (Third Edition)
  • PSQI score greater than 5
  • participants must voluntarily agree to participate in the trial after explanation by a physician and complete the informed consent form

Who cannot take part

  • currently using tranquilizers, hypnotics, or stimulant-related medications or substances (such as coffee or energy drinks)
  • patients with a history of significant head trauma
  • those with other severe medical conditions (e.g., hepatic or renal dysfunction)
  • those with allergies to dairy products
  • individuals with alcohol abuse within the past year
  • Pregnant women or breastfeeding mothers
  • participants unable to comply with the trial schedule
  • individuals on a vegetarian diet

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study investigates the impact of Aalpha-s1 casein hydrolysate (ACH; Lactium®) on sleep quality in individuals with chronic insomnia, employing both subjective sleep profiles and objective polysomnography (PSG) recordings.

The 2 groups in the trial

  • ACH (Aalpha-s1 casein hydrolysate)Treatment being tested

    Each participant will take Prelactium capsules (alpha-s2 casein hydrolysate supplement; 150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.

    Treatment: alpha-s1 casein hydrolysate

  • Placebo (Maltodextrin)Placebo, for comparison

    Each participant will take Maltodextrin capsules (150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.

    Treatment: Maltodextrin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Alpha-s1 Casein Hydrolysate for Patients With Chronic Insomnia: A Randomized Double-Blind Controlled Trial
Publications
Record updated
10 January 2024